IL143071A0 - Dispersible compositions containing l-dopa ethyl ester - Google Patents

Dispersible compositions containing l-dopa ethyl ester

Info

Publication number
IL143071A0
IL143071A0 IL14307199A IL14307199A IL143071A0 IL 143071 A0 IL143071 A0 IL 143071A0 IL 14307199 A IL14307199 A IL 14307199A IL 14307199 A IL14307199 A IL 14307199A IL 143071 A0 IL143071 A0 IL 143071A0
Authority
IL
Israel
Prior art keywords
ethyl ester
compositions containing
dopa ethyl
dispersible compositions
dispersible
Prior art date
Application number
IL14307199A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL143071A0 publication Critical patent/IL143071A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14307199A 1998-11-10 1999-11-10 Dispersible compositions containing l-dopa ethyl ester IL143071A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10789398P 1998-11-10 1998-11-10
PCT/US1999/026546 WO2000027385A1 (en) 1998-11-10 1999-11-10 Dispersible compositions containing l-dopa ethyl ester

Publications (1)

Publication Number Publication Date
IL143071A0 true IL143071A0 (en) 2002-04-21

Family

ID=22319025

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14307199A IL143071A0 (en) 1998-11-10 1999-11-10 Dispersible compositions containing l-dopa ethyl ester

Country Status (13)

Country Link
US (2) US6376545B1 (no)
EP (1) EP1135118A1 (no)
JP (1) JP2002529407A (no)
CN (1) CN1329487A (no)
AU (1) AU764742B2 (no)
CA (1) CA2350304A1 (no)
HK (1) HK1041441A1 (no)
HU (1) HUP0104586A3 (no)
IL (1) IL143071A0 (no)
NO (1) NO20012265L (no)
NZ (1) NZ512027A (no)
WO (1) WO2000027385A1 (no)
ZA (1) ZA200103527B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1329487A (zh) 1998-11-10 2002-01-02 特瓦制药工业有限公司 包含l－多巴乙酯的可分散组合物
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
WO2003041646A2 (en) 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CA2536175C (en) * 2003-08-29 2013-05-28 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
WO2005105035A2 (en) * 2004-04-29 2005-11-10 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Targeted nanoparticles for drug delivery
WO2006035414A2 (en) * 2004-09-30 2006-04-06 Ranbaxy Laboratories Limited Carbidopa and levodopa dispersible tablets
CA2613631A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
PL1948155T3 (pl) * 2006-06-28 2012-10-31 Chelsea Therapeutics Inc Kompozycje farmaceutyczne zawierające droksidopę
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
BRPI0808647A2 (pt) * 2007-03-09 2014-08-12 Chelsea Therapeutics Inc Método para tratar a síndrome de sensibilidade central, método para reduzir, eliminar ou prevenir a dor associada à fibromialgia, kit útil para o tratamento de uma síndrome de sensibilidade central.
ES2431570T3 (es) * 2007-05-07 2013-11-27 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
US20130017274A1 (en) * 2011-03-16 2013-01-17 Buck Institute For Research On Aging Low dose lithium in the treatment or prophylaxis of parkinson's disease
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3054929B1 (en) 2013-10-07 2020-08-05 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
PL3782617T3 (pl) * 2014-09-04 2024-06-24 Lobsor Pharmaceuticals Aktiebolag Farmaceutyczne kompozycje żelowe zawierające lewodopę, karbidopę i entakapon
EP3291872A4 (en) 2015-05-06 2019-02-13 SynAgile Corporation PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
DE2246013A1 (de) 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US3939253A (en) 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
ATE76747T1 (de) 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
SK282071B6 (sk) 1991-01-30 2001-10-08 The Wellcome Foundation Limited Tableta dispergovateľná vo vode a spôsob jej prípravy
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
CN1329487A (zh) 1998-11-10 2002-01-02 特瓦制药工业有限公司 包含l－多巴乙酯的可分散组合物

Also Published As

Publication number Publication date
HK1041441A1 (zh) 2002-07-12
NZ512027A (en) 2004-04-30
WO2000027385A1 (en) 2000-05-18
JP2002529407A (ja) 2002-09-10
CA2350304A1 (en) 2000-05-18
US6703424B2 (en) 2004-03-09
EP1135118A1 (en) 2001-09-26
NO20012265D0 (no) 2001-05-08
NO20012265L (no) 2001-07-03
HUP0104586A2 (en) 2002-06-29
CN1329487A (zh) 2002-01-02
HUP0104586A3 (en) 2002-12-28
ZA200103527B (en) 2002-05-09
US6376545B1 (en) 2002-04-23
AU1716800A (en) 2000-05-29
AU764742B2 (en) 2003-08-28
US20020151589A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
IL143071A0 (en) Dispersible compositions containing l-dopa ethyl ester
HUP0101047A3 (en) Combined vaccine compositions
PL341372A1 (en) Cellecoxibe containing compositions
IL137999A0 (en) Vaccine compositions
GB9811377D0 (en) Compositions
PL345511A1 (en) Fuel compositions containing propoxilate
GB9828861D0 (en) Compositions
GB2339693B (en) Anti-mollusc compositions
GB9905325D0 (en) Compositions
GB9812818D0 (en) Dentfrice compositions
GB9822158D0 (en) Compositions
GB9827291D0 (en) Compositions
GB9806810D0 (en) Compositions
GB2343376B (en) Stable apomorphine solution formulations
GB2336535B (en) Compositions
GB9809347D0 (en) Compositions
GB9827690D0 (en) Compositions
GB9816050D0 (en) Compositions
GB9818278D0 (en) Compositions
GB9925365D0 (en) Phospholipid compositions
HU9803024D0 (en) Oral compositions containing ubidekarenone
GB9806809D0 (en) Compositions
GB9824922D0 (en) Odour-neutralising compositions
GB9809572D0 (en) Compositions
GB9811582D0 (en) Compositions